Vaxil Bio Ltd Total Liabilities
Vaxil Bio Ltd total liabilities. Based on the latest financial reports, Vaxil Bio Ltd (VXL) has total liabilities worth CA$8.00K CAD (≈ $5.79K USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See operational self-sufficiency of Vaxil Bio Ltd to measure how many days the company can operate on defensive assets alone.
Total Liabilities of Vaxil Bio Ltd (2009–2024)
Total liabilities of Vaxil Bio Ltd from 2009 to 2024. This chart illustrates how Vaxil Bio Ltd's total liabilities have evolved over time, based on quarterly financial data. See cash generation quality of Vaxil Bio Ltd to measure how efficiently the company converts operating cash flow to free cash.
Vaxil Bio Ltd Competitors by Total Liabilities
The table below lists competitors of Vaxil Bio Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Inspiration Healthcare Group PLC
LSE:IHC
|
UK | GBX20.34 Million |
|
Premier Health of America Inc
V:PHA
|
Canada | CA$56.43 Million |
|
Tan Delta Systems PLC
LSE:TAND
|
UK | GBX335.02K |
|
CARLYLE COMMODIT.CORP.
F:BJ4
|
Germany | €342.77K |
|
Rubico Inc. Common Stock
NASDAQ:RUBI
|
USA | $99.32 Million |
|
JDC Group AG
XETRA:JDC
|
Germany | €174.34 Million |
|
Pennant International Group plc
LSE:PEN
|
UK | GBX5.25 Million |
|
Kazera Global PLC
LSE:KZG
|
UK | GBX2.00 Million |
Liability Composition Analysis (2009–2024)
This chart breaks down Vaxil Bio Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see VXL current and non-current assets.
Liquidity & Leverage Metrics
Vaxil Bio Ltd Total Liabilities Ratios Explained
Vaxil Bio Ltd total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 75.38 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.01 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.01 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Vaxil Bio Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Vaxil Bio Ltd (2009–2024)
The table below shows the annual total liabilities of Vaxil Bio Ltd from 2009 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CA$17.00K ≈ $12.30K |
-80.00% |
| 2023-12-31 | CA$85.00K ≈ $61.49K |
-79.01% |
| 2022-12-31 | CA$405.00K ≈ $292.97K |
-30.77% |
| 2021-12-31 | CA$585.00K ≈ $423.18K |
-31.74% |
| 2020-12-31 | CA$857.00K ≈ $619.94K |
+8.76% |
| 2019-12-31 | CA$788.00K ≈ $570.03K |
+73.19% |
| 2018-12-31 | CA$455.00K ≈ $329.14K |
-42.91% |
| 2017-12-31 | CA$797.00K ≈ $576.54K |
+42.07% |
| 2016-12-31 | CA$561.00K ≈ $405.82K |
+10.65% |
| 2015-12-31 | CA$507.00K ≈ $366.76K |
+523.25% |
| 2014-12-31 | CA$81.35K ≈ $58.85K |
+25.17% |
| 2013-12-31 | CA$64.99K ≈ $47.01K |
-67.34% |
| 2012-12-31 | CA$199.02K ≈ $143.97K |
+100.68% |
| 2011-12-31 | CA$99.17K ≈ $71.74K |
+159.81% |
| 2010-12-31 | CA$38.17K ≈ $27.61K |
+31.48% |
| 2009-12-31 | CA$29.03K ≈ $21.00K |
-- |
About Vaxil Bio Ltd
Vaxil Bio Ltd., a biotechnology company, focuses on a novel drug discovery and development platform based on signal peptides for infectious diseases and cancer. Its lead product candidate is ImMucin, a MUC1 SP-based vaccine that has completed a Phase 1/2 clinical trial for the treatment of multiple myeloma. The company is headquartered in Toronto, Canada.